Trademark Search in Canada

BARRIOLIDES

View On IC.GC.CA

REGISTERED

on 5 Feb 2024

Last Applicant/ Owned by

EPIENDO PHARMACEUTICALS EHF.

Eiðistorg 13, Innovation Rouse 3rd FloorIS-170 Seltjarnames

Serial Number

2109678 filed on 20^th Oct 2020

Registration Number

TMA1220355 registered on 5^th Feb 2024

Registration expiry Date

20^th Oct 2030

Correspondent Address

FASKEN MARTINEAU DUMOULIN LLP

800 rue du Square Victoria, bureau 3500Montréal,

QUEBEC

H4Z1E9

BARRIOLIDES

Trademark usage description

active chemical ingredients for use in the manufacture of pharmaceuticals. pharmaceutical and veterinary preparations to improve function of membrane Read More

Classification Information

Class [001]
Active chemical ingredients for use in the manufacture of pharmaceuticals.

Classification kind code

Class [005]
Pharmaceutical and veterinary preparations to improve function of membranes in the body; pharmaceutical and veterinary preparations to improve function of membranes in the lung; pharmaceutical and veterinary preparations to enhance the epithelial barrier; pharmaceutical and veterinary preparations to enhance the airway epithelial barrier; pharmaceutical and veterinary preparations to inhibit inflammation; pharmaceutical and veterinary preparations for the treatment of a disease or condition that is caused by a defect in epithelial cells or tissue; pharmaceutical and veterinary preparations for the treatment of a disease or condition that benefits from enhancement or restoration of epithelial barrier function; pharmaceutical and veterinary preparations for the treatment of a disease or condition of epithelial tissue in the respiratory tract; pharmaceutical and veterinary preparations for the treatment of epithelial dysfunction; pharmaceutical and veterinary preparations for the treatment of human airway epithelial cells; pharmaceutical and veterinary preparations for the treatment of chronic respiratory diseases; pharmaceutical and veterinary preparations for the treatment of viral airways diseases; pharmaceutical and veterinary preparations for the treatment of an airways disease; pharmaceutical and veterinary preparations for the treatment of asthma; pharmaceutical and veterinary preparations for the treatment of chronic obstructive pulmonary disease (COPD); pharmaceutical and veterinary preparations for the treatment of cystic fibrosis; pharmaceutical and veterinary preparations for the treatment of non-cystic fibrosis bronchiectasis; pharmaceutical and veterinary preparations for the treatment of chronic rhinosinusitis; pharmaceutical and veterinary preparations for the treatment of diffuse panbronchiolitis (DPB); pharmaceutical and veterinary preparations for the treatment of chronic bronchitis; pharmaceutical and veterinary preparations for the treatment of bronchiolitis obliterans organizing pneumonia (BOOP); pharmaceutical and veterinary preparations for the treatment of infantile respiratory distress syndrome (IRDS); pharmaceutical and veterinary preparations for the treatment of bronchopulmonary dysplasia; pharmaceutical and veterinary preparations for the treatment of neuromuscular respiratory depression or failure; pharmaceutical and veterinary preparations for the treatment of pneumonia; pharmaceutical and veterinary preparations for the treatment of conditions caused by and associated with respiratory syncytial virus (RSV) and related viruses; pharmaceutical and veterinary preparations for the treatment of a disease or condition commonly associated with inflammation that benefits from enhancement or restoration of epithelial barrier function; pharmaceutical and veterinary preparations for the treatment of systemic inflammatory distress syndrome (SIRS); pharmaceutical and veterinary preparations for the treatment of adult respiratory distress syndrome (ARDS); pharmaceutical and veterinary preparations for the treatment of inflammatory bowel disease; pharmaceutical and veterinary preparations for the treatment of ulcerative colitis; pharmaceutical and veterinary preparations for the treatment of Crohn's disease; dietary supplements for general health and wellbeing, dietary supplements for maintaining a healthy digestive system, dietary supplements for enhancing the immune system.

Classification kind code

Class [042]
Scientific research in the field of pharmacology, pharmaceuticals, and biochemistry, pharmaceutical research and development; industrial analysis and research services in the field of pharmaceuticals.

Classification kind code

Mark Details

Serial Number

2109678

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 48 on 7^th Nov 2022	Agent Changed
Submitted for opposition 22 on 2^th Sept 2022	Search Recorded
Submitted for opposition 20 on 2^th Sept 2022	Examiner's First Report
Submitted for opposition 223 on 2^th Sept 2022	Total Provisional Refusal
Submitted for opposition 256 on 28^th Mar 2022	Notification of Possible Opposition Sent
Submitted for opposition 257 on 27^th May 2021	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 26^th May 2021	Formalized
Submitted for opposition 1 on 26^th May 2021	Created
Submitted for opposition 228 on 20^th Oct 2020	International Registration
Submitted for opposition 30 on 20^th Oct 2020	Filed

BARRIOLIDES

Classification Information

Class [001]Active chemical ingredients for use in the manufacture of pharmaceuticals.

Classification kind code

Classification kind code

Class [042]Scientific research in the field of pharmacology, pharmaceuticals, and biochemistry, pharmaceutical research and development; industrial analysis and research services in the field of pharmaceuticals.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [001]
Active chemical ingredients for use in the manufacture of pharmaceuticals.

Class [042]
Scientific research in the field of pharmacology, pharmaceuticals, and biochemistry, pharmaceutical research and development; industrial analysis and research services in the field of pharmaceuticals.